Connect with us

Pandemic

US coronavirus: The slowing Covid-19 vaccination rate is worrying experts. Here’s what some states are doing to change the trend

Published

on

About 1.4 million new doses of Covid-19 vaccines have been administered since Thursday, bringing the seven-day average of administered doses back to just over 1 million doses per day. By the beginning of the week it had dropped to below a million a day on average.

However, those numbers are below an early April average high of 3.3 million per day.

Dr. Anthony Fauci, director of the National Institute for Allergies and Infectious Diseases, said Friday that the best way for the country to avoid another Covid-19 surge – and shutdown – is to get vaccinated.

“It’s not over until it’s over – and it’s not over yet,” Fauci said at a U.S. Health and Social Services event, urging people to be careful not to believe the pandemic is over .

A recent CNN analysis of CDC data found that the pace of newly vaccinated adults will not meet the Biden government’s goal of 70% of adults with a dose by July 4th. late July.

Currently, 12 states have reached Biden’s single dose goal: California, Connecticut, Hawaii, Massachusetts, Maryland, Maine, New Hampshire, New Jersey, New Mexico, Pennsylvania, Rhode Island, and Vermont.

The urge to increase vaccinations is underscored by further evidence that the mass vaccination programs this year have made a huge contribution to the fight against Covid-19.

Over the past month, the number of deaths from Covid-19 has dropped noticeably, and confirmed cases continue to decline compared to previous highs, according to CDC data.

A daily average of 49,000 new cases reported to the CDC in early May fell to less than 14,000 on Thursday. During the holiday wave of infections last winter, the daily average of new cases was 250,000.

Almost 170 million people – just over half the total US population – have received at least one dose of vaccine, and approximately 137.5 million people – 41.4% of the population – are fully vaccinated.

Incentives for vaccines go further

A variety of states and corporations last month hoped to create demand for vaccines by giving prizes to those vaccinated.

The latest is Hawaii which has a variety of donated prizes, including vacation packages and airline miles, to help you reach vaccination milestones as soon as possible.

“The past 15 or 16 months have been a very difficult time for our tourism sector,” said Peter Ingram, President and CEO of Hawaiian Airlines.

Poll: Two-thirds of Americans say life is at least a little bit back to normal before the pandemic

Hawaii, which has maintained some of the strictest travel restrictions throughout the pandemic, is starting to relax the rules on air travel and lifting its testing and quarantine requirements for people flying between the Hawaiian islands from June 15, vaccination rate reaches 70% announced the state.

“We have to work hard now to get to the point where Safe Travels is no longer necessary to keep the people of Hawaii safe,” said Governor David Ige on Friday.

In Kentucky, Governor Andy Beshear announced the state’s new Covid-19 vaccine incentive that will give vaccinated adults “a million dollar chance,” he said.

“In the coming weeks, three vaccinated Kentuckers, ages 18 or older, will become millionaires,” Beshear said Friday, adding that 15 Kentuckers ages 12 to 17 are receiving full scholarships to a state public college, university, or technical or business school become.

More than 2 million Kentuckers have been vaccinated, but Beshear expects “a significant increase,” he said following Friday’s announcement.

In Colorado, Governor Jared Polis presented Sally Sliger with an oversized check for $ 1 million as the winner of the state’s first ‘Comeback Cash’ initiative.

Sliger said she is a lifetime resident of Colorado and currently resides in the town of Mead with her husband and two children.

“The likelihood that my family and me would get a million dollars overnight seemed incredibly slim,” said Sliger, encouraging everyone to get vaccinated for freedom. “It was of course surreal.”

Protecting children remains a priority

As vaccines continue to find their way into the arms of eligible teenagers and adults, health officials remain concerned about the safety of children. Only people aged 12 and over can currently receive a Covid-19 vaccine in the United States.

Research showing an increase in hospital admission rates for Covid-19 among teenagers in the United States is a reminder that even children can suffer from the virus, said Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, on Friday.Caught in a

“It tells you that children are still suffering from this virus and can be hospitalized,” Offit told CNN’s Jake Tapper. “We initially had this idea that this was just a disease of the elderly. That’s not true. This virus can also harm children.”

As a result, school mask bans in states like Texas are irresponsible and could lead to more children becoming sick, Offit said.

“Having rules like this that just encourage the spread of this virus – which only result in more children getting sick – is just nonsensical,” he said.

The CDC says vaccinated people can stop wearing masks in most cases, but unvaccinated people should keep using them.

The FDA’s Advisory Committee on Vaccines and Related Biological Products (VRBPAC), of which Offit is a member, will meet on June 10 to discuss what the FDA is considering when approving or approving the use of coronavirus vaccines in children under the age of 12 should.

Both Moderna and Pfizer are conducting studies for their vaccines in children under the age of 11.

Contributors to this report were Deidre McPhillips, Lauren Mascarenhas, Michael Nedelman, Andy Rose, Melissa Alonso, Naomi Thomas and Hannah Sarisohn of CNN.

Pandemic

Novavax Offers U.S. a Fourth Strong Covid-19 Vaccine

Published

on

Novavax, a small American company that has benefited from generous support from the U.S. government, announced the results of a clinical trial of its Covid-19 vaccine in the United States and Mexico on Monday, finding that its two-shot vaccine had one offers effective protection against the coronavirus.

In the 29,960-person study, the vaccine showed an overall effectiveness of 90.4 percent, on par with the vaccines from Pfizer-BioNTech and Moderna and higher than the single-use vaccine from Johnson & Johnson. The Novavax vaccine showed 100 percent effectiveness in preventing moderate or severe illness.

Despite these impressive results, the future of the vaccine in the United States remains uncertain and may be needed more in other countries. Novavax says it may not seek emergency clearance from the Food and Drug Administration until the end of September. And with an ample supply of three other approved vaccines, the agency may instruct Novavax to apply for a full license instead – a process that could take several additional months.

The company’s CEO, Stanley Erck, admitted in an interview that Novavax would likely get its first approval elsewhere. The company is also applying in the UK, the European Union, India and South Korea.

“I think the good news is that the data is so compelling that it gives anyone an incentive to pay attention to our records,” said Mr. Erck.

If Novavax gets the green light from the US government, it could be too late to contribute to the country’s first wave of vaccinations. However, many vaccine experts believe that as immunity declines and variants emerge, the country will eventually need booster vaccinations. And the protein-based technology used in the Novavax vaccine can do a particularly good job of enhancing protection, even if people have previously been vaccinated with a different formulation.

“They really can be the right ones for boosters,” said Dr. Luciana Borio, who was the acting Chief Scientist of the FDA from 2015 to 2017.

Last year, the Trump administration’s Operation Warp Speed ​​program awarded Novavax a $ 1.6 billion contract for 100 million future cans. The company gained this tremendous support despite not having launched a vaccine in over three decades.

In January, Novavax announced that its 15,000-person study in the UK found the vaccine to be 96 percent effective against the original coronavirus. Against Alpha, a virus variant identified for the first time in Great Britain, the effectiveness fell slightly to 86 percent. In South Africa, where Novavax conducted a smaller study of 2,900 people and dominated the beta variant, the company found an effectiveness of only 49 percent.

However, the study in South Africa was made difficult by the fact that some of the volunteers had HIV, which is known to interfere with vaccination. In addition, the study was so small that it was difficult to gauge how much protection the vaccine would offer HIV-negative volunteers.

With the support of Operation Warp Speed, Novavax made plans for an even larger late-stage trial in the United States and Mexico. But manufacturing difficulties delayed the launch until December.

By then, the United States had approved the Pfizer-BioNTech and Moderna vaccines. In February, while the Novavax trial was still ongoing, the Johnson & Johnson’s government approved.

While Novavax waited for the study results, Novavax has teamed up with other companies to begin manufacturing massive quantities of its vaccine. In India it has partnered with the Serum Institute and in South Korea with SK Biosciences. Novavax has reached an agreement with Gavi, the Vaccine Alliance, to supply 1.1 billion doses to middle and low income countries.

The company’s scaling difficulties persisted, however, and it took more time to develop specific tests to validate the quality of its product.

The new results were based on 77 test subjects who contracted Covid-19. The volunteers who received the placebo injections got sick far more often than the vaccinated, a statistical difference that led to an effectiveness of 90.4 percent.

“That’s a strong result,” said Natalie Dean, biostatistician at the University of Florida. “It takes you to this high level.”

The vaccine showed the same effectiveness in a group of high-risk volunteers – people who were over 65 years old, had medical risk factors, or had jobs that exposed them to the virus.

Novavax sequenced the genomes of 54 of the 77 virus samples and found that half were alpha, the variant that became predominant in the United States that spring.

The side effects of the vaccine were relatively mild. Some volunteers reported fatigue, headaches, and other minor symptoms. “This vaccine seems to make the arms lighter,” said John Moore, a virologist at Weill Cornell Medicine who volunteered in the Novavax study.

Novavax will file for approval in the US after it completes the development of a quality control test, the managing director said. “You definitely have to test them from Sunday to show that you get the same answer under all conditions,” said Erck. “And that takes time.”

Mr. Erck said the company plans to produce 100 million cans per month by the end of the third quarter and 150 million cans per month by the end of the fourth quarter.

Every week the United States is building up a wider range of approved vaccines from other companies, raising the question of whether the country needs to issue more emergency permits or EUAs.

“The law says that once you have adequate doses, no additional EUAs are required,” said Dr. Borio.

A sign that the FDA is changing its approach to Covid-19 vaccines came last week. An American company called Ocugen had applied for an emergency permit for Covaxin, a Covid-19 vaccine that is now used in India. However, on Thursday the company announced that the FDA had recommended that the standard route to full approval be followed instead, the so-called biologics license application, which takes many additional months.

However, since Novavax has been consulting with the FDA about its studies since last year, Mr. Erck said the company may be able to continue its plans to apply for an emergency clearance.

“So far you have indicated that if you are in favor of an EEA, you can proceed for an EEA,” said Mr Erck. “Anyone could tell you that could change, but I don’t know how to predict it.”

Dr. Paul Offit, a professor at the University of Pennsylvania and a member of the FDA’s Vaccine Advisory Panel, said Novavax’s potent vaccine is most welcome. “The more the better,” he said. “I think there is room for a lot more vaccines because we will be dealing with this virus for years, if not decades.”

Novavax is preparing for this future by researching how its vaccine could work as a booster. A new version of the vaccine contains the proteins of the beta variant first identified in South Africa.

Researchers gave baboons beta boosters that had been vaccinated a year ago in experiments with the original version of the Novavax vaccine. The researchers found that the baboon’s immunity to Covid-19 skyrocketed after this booster, protecting them from beta, alpha, and the original version of the coronavirus.

“When you boost, you see a very high recall response,” said Matthew Frieman, a virologist at the University of Maryland School of Medicine and co-author of the new study. The study has not yet been published in a scientific journal.

Dr. Frieman said the new study offers encouraging evidence that Novavax vaccines might work well as boosters. It also suggested that first-time vaccines people might do well to get a mix of the original and beta versions to expand their protection against new variants, he said.

“Novavax can be used as a booster in the US, but it will certainly be the first vaccine many people around the world will see,” he said.

Continue Reading

Pandemic

To Fix Healthcare After Covid-19, Doctors Must Have The Courage To Change

Published

on

Doctors showed great courage during the Covid-19 pandemic. Now you have to show the courage to change … [+] the job.

getty

Long before doctors battled the coronavirus, their professional ancestors risked their lives fighting the Black Death.

Throughout history, doctors have shown courage: the ability to act regardless of risk or fear.

Think sawing off a gangrenous limb or having brain surgery or treating a disease like Ebola which kills up to 90% of the people it infects. In these harrowing situations, courage alone is not enough. Doctors too, to a certain extent, have to deny objective reality. You need to suppress the existence of fear, detach yourself from its emotions, not admit weaknesses, deny any pain, show single-minded attention to the task at hand, and extinguish any feelings that are trying to escape in the process.

Until recently, no one questioned whether such extreme denial was mentally healthy. The doctors just thought it was necessary.

Courage and denial remain cultural imperatives in today’s profession. These properties are taught to every medical student and hardwired in every doctor.

And they have some unfortunate and tragic side effects.

I remember a talented doctor who returned to work the day after she received a final diagnosis herself. None of her colleagues, friends or patients knew about her illness until she died. In medical culture, this type of emotional distance is the rule, not the exception.

As a nation, we are indebted for the courage and refusal of our doctors. Without their courage and sacrifices over the past year and a half, Covid-19 would have killed many more of our friends and loved ones.

But now that our country has weathered the worst of the pandemic, it is time to address the American health care failures that harmed doctors and patients long before the coronavirus hit land. To do this, doctors need to play a leadership role both in transforming the health system and in challenging their own cultural assumptions.

These changes require more courage and less denial.

1. The courage to ask for help

In a recent article, I wrote about three critical care physicians who had recently gone through hell.

A doctor, a resident, had started his rotation in the intensive care unit with half a dozen Covid-19 patients under his care. All were dead by the end of the month. Another doctor, a die-hard ICU veteran, said she woke up in sweat every day before dawn. The third, a senior officer, watched four of his patients die in a single day.

Psychological defense mechanisms such as denial help doctors suppress fear and bypass grief over the loss of a patient. But as with any coping mechanism, denial is best used in moderation, not permanently. No level of denial, repression, harshness, or hardship could have prepared health care workers for the flood of death that Covid-19 wreaked. No amount of cultural conditioning could adequately prepare clinicians for the pain they have endured. As a result, many feel exhausted at work.

As the saying goes: “You can’t pour from an empty cup”. Too many cups are empty.

According to Medscape’s latest physician survey, 42% of all physicians are burned out. But only 7% of them say they see a therapist to improve their mental health.

It takes courage to challenge the medical profession’s culture of harshness and emotional repression. Doctors need a lot of strength to recognize their limits. And it takes courage to seek help when it is needed.

2. The courage to recognize one’s prejudices

It has become the standard in American culture to point your finger at others and blame others. Doctors are no different. On social media and at medical conferences, doctors are seldom willing to take responsibility for any of the many health care issues.

Take health differences, for example. Ask doctors why black patients have shorter lifespans and poorer health outcomes than whites, and they will blame socio-economic factors such as income, education, and the ills of American health insurance. They point to social determinants (where people were born and raised, work, play and socialize) and social dynamics (such as racial segregation, poverty and educational barriers). Of course, these external factors contribute to health inequalities, but they are not the only factors that play a role.

Research shows that two-thirds of doctors have an implicit black bias. This type of bias is different from open hatred or even conscious bias. But it is no less harmful.

At the start of the pandemic, when test kits were scarce, doctors tested white patients twice as often as black patients with identical symptoms. This makes no logical sense, as black patients were two to three times more likely to die than white patients.

Bias also helps explain why black patients receive 40% less pain medication than white patients after surgery. And it helps us understand why the average black patient receives $ 1,800 less in total medical care per year than a white person with the same health problems.

For decades, doctors have insisted that health inequalities are the fault of American society, existing policy, or other actors in the health system. While we must address these barriers to better health for all, doctors must also show the courage to hold up the mirror to the profession. After all, it is they who decide which patients will be tested and how much pain medication will be given.

Until doctors have the courage to face their prejudices, they will continue to violate the sacred oath of medicine to “do no harm first.”

3. The courage to treat patients like health partners

In the 21st century, the internet has flattened the gap between the experts and everyone else. In healthcare today, patients can explore diseases and treatments in unprecedented depth.

Many doctors believe that weeding out health information from the Internet is a recipe for “bad medicine.” May be. But doctors can’t expect patients to just stop looking for evidence on the internet. It’s not that people are suddenly asking for less information, less transparency, or less convenience from healthcare or other services.

American consumer culture is not going to go away. As a result, more and more Americans are demanding a new kind of doctor-patient relationship – one that looks far less paternalistic and more like a partnership. And this partnership must take into account the needs and wishes of the patient.

Telemedicine is a good place to start. Before the pandemic, only 8% of Americans had had a “virtual visit” to a doctor. Because most doctors had insisted that a good doctor’s practice can only take place in person. Covid-19 has proven that this perception is wrong. A recent survey found that 20% of consumers (55 million Americans) would trade their doctor for a doctor who offers telemedicine.

Historically, doctors have not valued or prioritized the patient’s time, convenience, or preferences. In the future, they won’t have a choice. A more equal doctor-patient partnership requires the courage to embrace alternative approaches to treatment and accept that patients have become (and will remain) savvy healthcare consumers.

4. The courage to uphold the true mission and purpose of medicine

For most of medical history, illnesses plagued doctors. Epidemics killed millions, including doctors who comforted the sick and dying. Entire civilizations died a gruesome death with doctors at their sick beds. And yet doctors never lost their nerve or the desire to help.

Many doctors today feel like victims of a broken system. They blame for-profit insurers, greedy pharmaceutical company executives, and hospital administrators for their professional dissatisfaction. And while they are right to call for sweeping health reforms that will free them from the administrative distractions that keep them from doing their jobs, they must also show the courage to change what they can control.

Doctors are the ones who write the prescriptions that contribute to 60,000 opioid deaths each year. They sign the surprising medical bills that have bankrupted millions of patients and their families. They contribute to the preventable medical errors that kill 200,000 people each year. They perform the 30% of all procedures that researchers at the Mayo Clinic have shown have no clinical value.

American doctors are at a crossroads. You are part of a wonderful and beautiful profession that is currently in crisis. Doctors must continue to uphold the righteous mission and purpose of medical culture. At the same time, they must have the courage to develop the most problematic parts of the culture. Not only does this benefit patients, but it also restores the appreciation the profession deserves.

Continue Reading

Pandemic

As COVID-19 cases wane, vaccine-lagging areas still see risk – The Denver Post

Published

on

JACKSON, miss. – New COVID-19 cases are declining in most of the country, even in some states with vaccine-reluctant populations. But almost all states bucking this trend have below-average vaccination rates, and experts warn that pandemic relief in regions where few people are vaccinated may be temporary.

According to data from Johns Hopkins University, case numbers nationwide fell from a seven-day average of nearly 21,000 on May 29 to 14,315 on Saturday in one week. For weeks, states and cities have also been dropping virus restrictions and mask requirements indoors.

Experts said some states are seeing increased immunity because the disease has a high natural rate of spread, killing nearly 600,000 Americans to date.

“We certainly have some benefit to the population from our previous cases, but we paid for it,” said Dr. Thomas Dobbs, Mississippi State Health Commissioner. “We paid for it with deaths.”

More than 7,300 Mississippi residents have died from the pandemic, and the state has the sixth highest death rate per capita.

Dobbs estimates that about 60% of the state’s residents have “some underlying immunity”.

“We are most likely seeing this effect now because we have a combination of natural and vaccine-induced immunity,” said Dobbs.

Only eight states – Alabama, Arkansas, Hawaii, Missouri, Nevada, Texas, Utah, and Wyoming – have seen a seven-day moving average for infection rates from two weeks earlier, according to Johns Hopkins University. All of them except Hawaii have fully vaccinated lower than the US average of 39.7%, according to the US Centers for Disease Control and Prevention.

The 10 states with the fewest new cases per capita during this period all have fully vaccinated rates above the national average. These include the three most vaccinated states: Vermont, Massachusetts, and Connecticut.

Medical experts said a number of factors were playing a role in the decline in case numbers across the country, including vaccines, natural immunity to exposure to the virus, warmer weather, and people spending less time indoors.

But dr. Leana Wen, a public health professor at George Washington University, said she was concerned that the natural immunity of those exposed to the coronavirus could soon wane. And she worries that states with low vaccination rates could become hot spots.

“Just because we’re lucky in June doesn’t mean we’ll continue to be lucky through late fall and winter,” said Wen, former Baltimore city health commissioner. “We could have variants here that are more transmissible and more virulent, and those that have no immunity or have declining immunity could be vulnerable again.”

In Mississippi, about 835,000 people are fully vaccinated, or 28% of the population, compared to the national average of 43%. But despite the lagging vaccination rate, the state’s moving average of new daily infections has declined by about 18% in the past two weeks, according to Johns Hopkins.

Dr. Albert Ko, chairman of the Department of Microbial Disease Epidemiology at Yale, said there was no accurate data to show the percentage of the population in “high exposure” states like Alabama and Texas, but he said estimates assume up to 50%.

“I think it doesn’t deny the importance of vaccination, especially because the antibody levels produced by natural infections are lower than what we have for our best vaccine,” Ko said.

Ko said it is important that those who have been exposed to the disease also get vaccinated because natural immunity doesn’t last as long as vaccine immunity and antibody levels are lower.

Wen said research strongly suggests that vaccinations are beneficial for those who already have antibodies from infection.

“I think it’s a fallacy that many people don’t need to be vaccinated after they recover,” she said.

___

Pat Eaton-Robb contributed to this report from Connecticut.

Continue Reading
Advertisement

Trending